YH006

YH006 is a potentially first-in-class CTLA-4/OX40 bispecific antibody for the treatment of solid tumors. YH006 simultaneously binds both CTLA-4 and OX40 to enhance antineoplastic activity while at the same time decreasing the adverse effects immunotherapy. It is currently at CMC stage.

Back to top